(Q35976827)

11 August 2017

1 reference

title

Pharmacologic treatment of type 2 diabetic dyslipidemia (English)

1 reference

11 August 2017

1 reference

Yong S K Moon

1

1 reference

PubMed ID

15585439

11 August 2017

Moti L Kashyap

series ordinal

2

1 reference

PubMed ID

15585439

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

24

1 reference

11 August 2017

12

1 reference

11 August 2017

1692-1713

1 reference

Diabetes, hyperlipidemia, and coronary artery disease

11 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Management of dyslipidemia in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

An overview of metformin in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Comparative tolerability of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

How well tolerated are lipid-lowering drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Fish oil and glycemic control in diabetes. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Mechanism of action of niacin on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The benefits of niacin in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Mechanistic studies of high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Lipoprotein Lp(a) excess and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Evaluating niacin in its various forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Postmenopausal hormone replacement therapy as antiatherosclerotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

Strategies for the management of diabetic dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1692.52340

10.1592/PHCO.24.17.1692.52340

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15585439